Skip to content

Study · Randomized controlled trial · 2025

3 results

Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.

Tchang BG, Knight MG, Adelborg K, Clements JN, Iversen AT, Traina A

Obesity (Silver Spring, Md.)5 Jan 2025Cited by 5 (Europe PMC)

PMID39756397 (opens in a new tab)PMCIDPMC11774009 (opens in a new tab)DOI10.1002/oby.24202 (opens in a new tab)PepBankPUB-39756397
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with overweight or obesity, a higher proportion on semaglutide 2.4 mg than placebo had antihypertensive or lipid-lowering treatment intensity reduced by end of treatment.

    In plain wordsIn people with overweight or obesity, more people on semaglutide 2.4 mg than on placebo needed less blood pressure or cholesterol medicine.

    Peptide
    Semaglutide
    Outcome
    IncreaseAntihypertensive or lipid-lowering treatment intensity reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mgAs given in this study (human).

    Source sentences

    Summary
    In both pooled samples, a higher proportion of participants in the semaglutide 2.4 mg group versus placebo underwent antihypertensive or lipid-lowering treatment intensity reduction by end of treatment.
    1 context sentence
    Summary · context
    In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with overweight or obesity, a smaller proportion on semaglutide 2.4 mg than placebo had antihypertensive or lipid-lowering treatment intensified by end of treatment.

    In plain wordsIn people with overweight or obesity, fewer people on semaglutide 2.4 mg than on placebo needed more blood pressure or cholesterol medicine.

    Peptide
    Semaglutide
    Outcome
    DecreaseAntihypertensive or lipid-lowering treatment intensification
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mgAs given in this study (human).

    Source sentences

    Summary
    A smaller proportion underwent antihypertensive or lipid-lowering treatment intensification by end of treatment in the semaglutide 2.4 mg group of both samples versus placebo.
    1 context sentence
    Summary · context
    In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In participants taking antihypertensive or lipid-lowering medications, body weight fell numerically more with semaglutide 2.4 mg than with placebo.

    In plain wordsIn people taking blood pressure or cholesterol medicines, body weight fell more with semaglutide 2.4 mg than with placebo, by numbers only.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction in participants taking antihypertensive or lipid-lowering medications
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mgAs given in this study (human).

    Source sentences

    Summary
    In participants receiving antihypertensive or lipid-lowering medications in both samples, greater numeric reductions in body weight were observed in the semaglutide 2.4 mg group versus placebo.
    1 context sentence
    Summary · context
    In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.